ORGANOIDSCIENCES
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-… Read more
ORGANOIDSCIENCES - Asset Resilience Ratio
ORGANOIDSCIENCES (476040) has an Asset Resilience Ratio of 61.86% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how ORGANOIDSCIENCES's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ORGANOIDSCIENCES's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.77 Billion | 6.85% |
| Short-term Investments | ₩14.24 Billion | 55.01% |
| Total Liquid Assets | ₩16.02 Billion | 61.86% |
Asset Resilience Insights
- Very High Liquidity: ORGANOIDSCIENCES maintains exceptional liquid asset reserves at 61.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ORGANOIDSCIENCES Industry Peers by Asset Resilience Ratio
Compare ORGANOIDSCIENCES's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for ORGANOIDSCIENCES (2022–2024)
The table below shows the annual Asset Resilience Ratio data for ORGANOIDSCIENCES.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 61.86% | ₩16.02 Billion | ₩25.89 Billion | -5.31pp |
| 2023-12-31 | 67.17% | ₩22.00 Billion | ₩32.76 Billion | -9.36pp |
| 2022-12-31 | 76.53% | ₩30.43 Billion | ₩39.76 Billion | -- |